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Lead author: Zhongheng Zhang; zh_zhang1984@hotmail.com Three part clinical question: Patients: Critically ill patients with acute renal failure that required continuous renal replacement therapy (CRRT). Intervention: Anticoagulation for continuous renal replacement therapy provided by regional citrate compared to control anticoagulation. Outcome: Primary outcomes -circuit life span, bleeding events, metabolic derangement and mortality. No secondary outcomes were identified.
The study: A meta-analysis of available randomised controlled trials (RCTs) from inception point until 15th June 2011.
Search terms: Citrate, continuous renal replacement therapy, haemofiltration, haemodialysis, hemodiafiltration.
Data source: Two authors independently researched four databases, Pubmed, Current Contents, CINAHL, and EMBASE, and recorded data on a custom made form. The quality of the studies was assessed on the basis of randomisation strategy, allocation concealment, blindness, incomplete data, and selective reporting. The corresponding authors were contacted if necessary when additional information was needed. The final results were compared to settle any disparities.
Study selection:
Inclusion criteria: Randomised controlled trials investigating the efficacy and safety of RCA were included. Anticoagulation strategies of the control arm were not restricted. The studies analysed were conducted in CRRT-treated critically ill patients.
Intervention group: Regional citrate as mode of anticoagulation for CRRT. Control: Systemic heparin, regional heparin and nadroparin. Exclusion criteria: Of 167 records identified through database searching, 157 were excluded because they were reviews, observational studies, retrospective studies, case reports or other studies. A further four were later excluded, two because they were non-randomised sequential trials, one because regional heparin was used in the treatment group and one because patients were allocated to the citrate group because they had contraindications to heparin use. Of the six studies included in the meta-analysis, the description of exclusion criteria differed significantly across studies and, in particular, patients with liver failure or at high risk of bleeding were excluded.
Data extraction: Six RCTs (comprising 658 circuits) were included in the meta-analysis. Four studies used systemic heparin as the control, one used regional heparin, and one used nadroparin. Each of the six studies investigated circuit life span (658 circuits) and bleeding events (517 patients). Five out of the six studies (640 circuits) investigated for metabolic events, but results were reported in various ways making metaanalysis impossible. Conclusions were therefore drawn on the basis of a narrative review. In the meta-analysis, only two studies (370 patients) reported mortality.
Heterogeneity was assessed using I 2 . There was a significant level of heterogeneity across studies due to differences in patient characteristics, accepted definitions of primary outcomes, CRRT modalities, filter materials and anticoagulation modes in the control group.
The evidence:
The six papers analysed looked at several outcome parameters comparing control and citrate anticoagulation. Citrate was Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy 1A02, 3C00
A meta-analysis of randomised controlled trials comparing regional citrate anticoagulation (RCA) to control anticoagulation for haemofiltration revealed that citrate anticoagulation is effective at maintaining circuit patency and reducing the risk of bleeding during haemofiltration. The use of regional citrate anticoagulation also prolongs the haemofiltration circuit life, but this result is not significant when compared to the use of heparin. There was however, marked heterogeneity between trials reported.
Level of evidence: 1-(Meta-analysis with a high risk of bias)
Appraised by: JR Sheehan, M Ezra associated with a significantly longer circuit survival in three of the studies, with a mean difference of 23.03 hours (95% CI 0.45-45.61 hours). In five of the studies in the meta-analysis, citrate was associated with fewer bleeding events than in the control group. In the remaining study, there was no increase in bleeding events in either the citrate or control arms. Due to differences in reporting of results, a narrative review of metabolic events was performed; no significant difference in episodes of hypernatremia or bicarbonate control were reported in the studies. However, two of the studies reported more episodes of alkalosis in the citrate group, whereas two of the studies reported more episodes of alkalosis in the control group. Four of the six studies looked at hypocalcaemia and each study reported more episodes of systemic hypocalcaemia in the citrate group, but none appeared to cause any clinically significant consequences. Two studies investigated the influence of citrate on mortality, with one study showing that mortality rates per day were similar between the citrate and control groups during both treatment and follow-up (3.1 vs 3.1% and 3.8 vs 3.4% respectively). In contrast, one study demonstrated that the citrate group had decreased both hospital and three-month mortality when compared with nadroparin, by 15% (p <0.05); post hoc analysis showed this result to be valid in subgroups of patients.
EBM questions: 1. Do the methods allow for adequate testing of the hypothesis?
Partially. The hypothesis is valid and worthy of further investigation. The statistical models used are also appropriate for testing the hypothesis with the data collected. However, there is significant heterogeneity among a small number of included studies with relatively small sample sizes and no agreed definitions or grading for measuring end points such as bleeding.
Do the statistical tests correctly test the results to allow differentiation of the statistically significant result? Yes.
However some of the results reported have very large confidence intervals. 3. Are the conclusions valid in light of the results? Yes.
• The authors concluded that in the pooled studies, regional citrate anticoagulation is effective at maintaining circuit patency and reducing the risk of bleeding. However, this is not statistically significant when compared to systemic heparin. • The safety of regional citrate anticoagulation in patients with liver failure cannot be assumed from this analysis. • The metabolic stability of regional citrate anticoagulation is comparable to other modes of anticoagulation. • There is limited evidence to assess whether there is any survival benefit from regional citrate anticoagulation. 4. Were results omitted and why? No. Of the six studies reviewed, no results were omitted from the analysis. However, there were incomplete data outcome in four studies, and conflicts of interest were disclosed in two studies. The authors of the meta-analysis felt this was unlikely to influence the results. In addition, because of the nature of the interventions, allocation concealment and study blinding were not performed and the authors concluded that the potential for bias was present and therefore that the quality of the included studies was not high. 5. Did the authors suggest further areas for research? Yes.
Implied in the discussion is that further work is needed in those patients with liver disease and those at a high risk of bleeding with a coagulopathy from any cause. The authors state explicitly that the impact of regional citrate anticoagulation on mortality is controversial on the basis of the present review, and that further studies are required to address this important issue for intensive care medicine. 6. Did the authors make any recommendations based on the results and were they appropriate? Yes. The authors recommend that regional citrate anticoagulation can be used for CRRT in certain groups of patients. 7. Is the study relevant to my clinical practice? Yes. Acute kidney injury requiring renal replacement therapy is very common in critically unwell patients being cared for on an intensive care unit (ICU). In addition, it is also common to have patients with liver disease and severe coagulopathy on an ICU. Ensuring that haemofiltration runs smoothly is important, as if filters clot, the therapeutic effects of haemofiltration are delayed, and as a consequence there will be increased workload and increased expense.
Researching ways to reduce these complications and to decrease patient mortality is clearly desirable. 8. What level of evidence does this study represent? 1 -. 9. What grade of recommendation can I make on this result alone? None. 10. What grade of recommendation can I make when this study is considered along with other available evidence? None. 11. Should I change my practice because of these results? No.
Due to the poor quality of the included studies and the significant heterogeneity among included studies, no valid conclusions can be drawn that would warrant a change in practice at this stage. 12. Should I audit my current practice because of these results?
Yes. We believe looking at the use of heparin in haemofiltration and the complications that arise from its use such as bleeding and need for transfusion may cause units to look more carefully at their protocol and consider ways to improve it, and consider the use of other agents that may have an improved safety profile over heparin, such as citrate.
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